Compile Data Set for Download or QSAR

Found 5357 hits with Last Name = 'bin' and Initial = 'h'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50095105 (4-{2-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-[1,...) Show SMILES CCCS(=O)(=O)N1CCC(CC1)N1CCC(CC1)C1(OCCO1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C29H38N2O8S2/c1-2-19-40(32,33)31-15-11-24(12-16-31)30-13-9-23(10-14-30)29(38-17-18-39-29)22-3-5-25(6-4-22)41(34,35)26-7-8-27-28(20-26)37-21-36-27/h3-8,20,23-24H,2,9-19,21H2,1H3	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	0.0100	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity at human cloned acetylcholine receptor M2 in CHO cells.				Bioorg Med Chem Lett 10: 2727-30 (2000) BindingDB Entry DOI: 10.7270/Q2V40TGZ
					More data for this Ligand-Target Pair
Calcitonin gene-related peptide type 1 receptor (Homo sapiens (Human))	BDBM50184069 (CHEMBL207197 | N-((R)-1-((S)-6-amino-1-oxo-1-(4-(p...) Show SMILES NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1 Show InChI InChI=1S/C38H47Br2N9O5/c39-29-21-25(22-30(40)34(29)50)23-33(45-37(53)48-15-10-28(11-16-48)49-24-26-5-1-2-6-31(26)44-38(49)54)35(51)43-32(7-3-4-12-41)36(52)47-19-17-46(18-20-47)27-8-13-42-14-9-27/h1-2,5-6,8-9,13-14,21-22,28,32-33,50H,3-4,7,10-12,15-20,23-24,41H2,(H,43,51)(H,44,54)(H,45,53)/t32-,33+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	Purchase CHEMBL MCE PC cid PC sid PDB UniChem Patents Similars	PDB Article PubMed	0.0100	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Vertex Pharmaceuticals Inc. Curated by ChEMBL					Assay Description Displacement of [125I]CGRP from CGRP receptor in human SK-N-MC cell membranes preincubated for 30 mins followed by radioligand addition measured afte...				Bioorg Med Chem Lett 24: 845-9 (2014) Article DOI: 10.1016/j.bmcl.2013.12.089 BindingDB Entry DOI: 10.7270/Q2FJ2J84
					More data for this Ligand-Target Pair				3D Structure (crystal)
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50095105 (4-{2-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-[1,...) Show SMILES CCCS(=O)(=O)N1CCC(CC1)N1CCC(CC1)C1(OCCO1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C29H38N2O8S2/c1-2-19-40(32,33)31-15-11-24(12-16-31)30-13-9-23(10-14-30)29(38-17-18-39-29)22-3-5-25(6-4-22)41(34,35)26-7-8-27-28(20-26)37-21-36-27/h3-8,20,23-24H,2,9-19,21H2,1H3	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	0.0100	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Antagonistic activity of the compound against Muscarinic acetylcholine receptor M2				Bioorg Med Chem Lett 11: 2311-4 (2001) BindingDB Entry DOI: 10.7270/Q28S4P7Z
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476758 (US10870660, Compound III-024 | US11345716, Compoun...) Show SMILES CN1Cc2c(cccc2C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(OCC(C)(F)F)nc4CC3)CC2)C1=O |r,wU:15.16,wD:12.12,(12.04,-1.54,;11.27,-.21,;9.74,-.05,;9.42,1.46,;10.75,2.23,;10.75,3.77,;9.42,4.54,;8.09,3.77,;8.09,2.23,;6.75,1.46,;6.75,-.08,;5.42,2.23,;4.08,1.46,;2.75,2.23,;1.42,1.46,;1.42,-.08,;.08,-.85,;-1.25,-.08,;-2.58,-.85,;-2.47,-2.39,;-3.6,-3.43,;-5.12,-3.21,;-5.89,-4.54,;-7.43,-4.54,;-8.2,-3.21,;-9.74,-3.21,;-10.51,-1.87,;-12.05,-1.87,;-12.82,-.54,;-12.05,-3.41,;-13.38,-2.64,;-7.43,-1.87,;-5.89,-1.87,;-5.33,-.44,;-3.86,.02,;2.75,-.85,;4.08,-.08,;11.9,1.2,;13.38,1.6,)| Show InChI InChI=1S/C30H38F2N4O3/c1-30(31,32)19-39-27-11-8-21-13-16-36(17-14-26(21)34-27)15-12-20-6-9-22(10-7-20)33-28(37)23-4-3-5-24-25(23)18-35(2)29(24)38/h3-5,8,11,20,22H,6-7,9-10,12-19H2,1-2H3,(H,33,37)/t20-,22-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0120	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476918 (US10870660, Compound II-057) Show SMILES Cn1cc2c(cccc2n1)C(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(OCC(F)F)nc3CC2)CC1 |r,wU:16.18,wD:13.14,(12.43,-1.54,;11.66,-.21,;10.13,-.05,;9.81,1.46,;8.48,2.23,;8.48,3.77,;9.81,4.54,;11.14,3.77,;11.14,2.23,;12.29,1.2,;7.14,1.46,;7.14,-.08,;5.81,2.23,;4.47,1.46,;3.14,2.23,;1.81,1.46,;1.81,-.08,;.47,-.85,;-.86,-.08,;-2.19,-.85,;-2.08,-2.39,;-3.21,-3.43,;-4.73,-3.21,;-5.5,-4.54,;-7.04,-4.54,;-7.81,-3.21,;-9.35,-3.21,;-10.12,-1.87,;-11.66,-1.87,;-12.43,-.54,;-12.43,-3.21,;-7.04,-1.87,;-5.5,-1.87,;-4.94,-.44,;-3.47,.02,;3.14,-.85,;4.47,-.08,)| Show InChI InChI=1S/C28H35F2N5O2/c1-34-17-23-22(3-2-4-25(23)33-34)28(36)31-21-8-5-19(6-9-21)11-14-35-15-12-20-7-10-27(37-18-26(29)30)32-24(20)13-16-35/h2-4,7,10,17,19,21,26H,5-6,8-9,11-16,18H2,1H3,(H,31,36)/t19-,21-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0140	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593894 (US11578084, Compound I'-42) Show SMILES Cn1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(OCC(C)(F)F)nc4CC3)CC2)n1 |r,wU:12.12,wD:9.8,(13.38,2.02,;11.84,2.02,;11.03,.71,;9.54,1.08,;9.42,2.61,;8.09,3.38,;6.75,2.61,;6.75,1.07,;5.42,3.38,;4.09,2.61,;2.75,3.38,;1.42,2.61,;1.42,1.07,;.09,.3,;-1.25,1.07,;-2.58,.3,;-2.47,-1.23,;-3.6,-2.28,;-5.12,-2.05,;-5.89,-3.38,;-7.43,-3.38,;-8.2,-2.05,;-9.74,-2.05,;-10.51,-.72,;-12.05,-.72,;-12.82,.62,;-12.05,-2.26,;-13.38,-1.49,;-7.43,-.72,;-5.89,-.72,;-5.33,.72,;-3.85,1.17,;2.75,.3,;4.09,1.07,;10.85,3.2,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0160	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
Calcitonin gene-related peptide type 1 receptor (Homo sapiens (Human))	BDBM50447327 (CHEMBL3114495) Show SMILES CC(C)N1CCN(CC1)c1c(F)cccc1C1SC(CC(=O)N2CCC(CC2)N2CCc3ccccc3NC2=O)C(=O)N1CCC(C)(C)C Show InChI InChI=1S/C38H53FN6O3S/c1-26(2)41-21-23-43(24-22-41)34-29(10-8-11-30(34)39)36-45(20-16-38(3,4)5)35(47)32(49-36)25-33(46)42-17-14-28(15-18-42)44-19-13-27-9-6-7-12-31(27)40-37(44)48/h6-12,26,28,32,36H,13-25H2,1-5H3,(H,40,48)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	0.0200	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Vertex Pharmaceuticals Inc. Curated by ChEMBL					Assay Description Displacement of [125I]CGRP from CGRP receptor in human SK-N-MC cell membranes preincubated for 30 mins followed by radioligand addition measured afte...				Bioorg Med Chem Lett 24: 845-9 (2014) Article DOI: 10.1016/j.bmcl.2013.12.089 BindingDB Entry DOI: 10.7270/Q2FJ2J84
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476915 (US10870660, Compound II-047) Show SMILES CN1Cc2c(cccc2C(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)C1=O |r,wU:15.16,wD:12.12,(11.97,-.99,;11.2,.35,;9.67,.51,;9.35,2.02,;10.68,2.79,;10.68,4.33,;9.35,5.1,;8.02,4.33,;8.02,2.79,;6.68,2.02,;6.68,.48,;5.35,2.79,;4.02,2.02,;2.68,2.79,;1.35,2.02,;1.35,.48,;.01,-.29,;-1.32,.48,;-2.65,-.29,;-3.86,.67,;-5.36,.32,;-6.03,-1.06,;-7.55,-1.27,;-7.83,-2.79,;-9.16,-3.56,;-10.49,-2.79,;-11.83,-3.56,;-11.83,-5.1,;-13.16,-4.33,;-13.16,-2.79,;-6.47,-3.52,;-5.36,-2.45,;-3.86,-2.79,;-2.65,-1.83,;2.68,-.29,;4.02,.48,;11.83,1.76,;13.16,2.53,)| Show InChI InChI=1S/C27H33F3N4O3S/c1-33-15-21-19(3-2-4-20(21)25(33)36)24(35)31-18-7-5-17(6-8-18)9-12-34-13-10-22-23(11-14-34)38-26(32-22)37-16-27(28,29)30/h2-4,17-18H,5-16H2,1H3,(H,31,35)/t17-,18-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0220	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593791 (US11578084, Compound I-074) Show SMILES Cn1cc(\C=C\C(=O)N[C@H]2CC[C@](F)(CCN3CCc4nc(OCC(C)(F)F)sc4CC3)CC2)cn1 |r,wU:12.13,wD:9.8,12.12,(13.61,4.08,;12.07,4.08,;11.17,2.83,;9.7,3.31,;8.37,2.54,;7.04,3.31,;5.7,2.54,;5.7,1,;4.37,3.31,;3.04,2.54,;1.7,3.31,;.37,2.54,;.37,1,;.37,-.54,;-.97,.23,;-2.3,1,;-3.63,.23,;-4.99,.96,;-6.4,.35,;-6.81,-1.2,;-8.28,-1.68,;-8.28,-3.22,;-9.61,-3.99,;-10.95,-3.22,;-12.28,-3.99,;-13.61,-3.22,;-13.05,-5.32,;-11.51,-5.32,;-6.81,-3.69,;-5.91,-2.45,;-4.37,-2.45,;-3.36,-1.29,;1.7,.23,;3.04,1,;9.7,4.85,;11.17,5.32,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0250	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476764 (US10870660, Compound III-064 | US11345716, Compoun...) Show SMILES CC(Oc1nc2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)c3cccc4C(=O)N(C)Cc34)CCc2s1)C(F)(F)F |r,wU:11.10,wD:14.17,(-10.47,-1.44,;-10.47,-2.98,;-9.14,-3.75,;-7.8,-2.98,;-7.64,-1.44,;-6.14,-1.12,;-5.57,.31,;-4.1,.76,;-2.83,-.1,;-1.5,.67,;-.16,-.1,;1.17,.67,;1.17,2.21,;2.5,2.98,;3.84,2.21,;3.84,.67,;2.5,-.1,;5.17,2.98,;6.51,2.21,;6.51,.67,;7.84,2.98,;7.84,4.52,;9.17,5.29,;10.51,4.52,;10.51,2.98,;11.65,1.95,;13.14,2.34,;11.02,.54,;11.79,-.8,;9.49,.7,;9.17,2.21,;-2.71,-1.64,;-3.84,-2.69,;-5.37,-2.46,;-6.4,-3.6,;-11.8,-3.75,;-13.14,-2.98,;-11.8,-5.29,;-13.14,-4.52,)| Show InChI InChI=1S/C28H35F3N4O3S/c1-17(28(29,30)31)38-27-33-23-11-14-35(15-12-24(23)39-27)13-10-18-6-8-19(9-7-18)32-25(36)20-4-3-5-21-22(20)16-34(2)26(21)37/h3-5,17-19H,6-16H2,1-2H3,(H,32,36)/t17?,18-,19-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0260	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593940 (US11578084, Compound III-3) Show SMILES Cc1cc(CC(=O)N[C@H]2CC[C@](F)(CCN3CCc4ccc(CCC(F)(F)F)nc4CC3)CC2)on1 |r,wU:11.12,wD:8.7,11.11,(13.49,2.1,;11.95,2.1,;10.92,3.24,;9.52,2.61,;8.18,3.38,;6.85,2.61,;6.85,1.07,;5.52,3.38,;4.18,2.61,;2.85,3.38,;1.51,2.61,;1.51,1.07,;1.51,-.47,;.18,.3,;-1.15,1.07,;-2.49,.3,;-2.37,-1.23,;-3.5,-2.28,;-5.02,-2.05,;-5.79,-3.38,;-7.33,-3.38,;-8.1,-2.05,;-9.64,-2.05,;-10.41,-.72,;-11.95,-.72,;-12.72,.62,;-13.49,-.72,;-12.72,-2.05,;-7.33,-.72,;-5.79,-.72,;-5.23,.72,;-3.76,1.17,;2.85,.3,;4.18,1.07,;9.68,1.08,;11.18,.76,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0290	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593929 (US11578084, Compound I-157) Show SMILES Cc1cc(CC(=O)N[C@H]2CC[C@](F)(CCN3CCc4ccc(CCC(F)(F)F)nc4CC3)CC2)on1 |r,wU:11.12,wD:11.11,8.7,(13.46,1.84,;11.92,1.84,;11.01,3.09,;9.55,2.61,;8.22,3.38,;6.88,2.61,;6.88,1.07,;5.55,3.38,;4.22,2.61,;2.88,3.38,;1.55,2.61,;1.55,1.07,;1.55,-.47,;.21,.3,;-1.12,1.07,;-2.45,.3,;-2.34,-1.23,;-3.47,-2.28,;-4.99,-2.05,;-5.76,-3.38,;-7.3,-3.38,;-8.07,-2.05,;-9.61,-2.05,;-10.38,-.72,;-11.92,-.72,;-12.69,.62,;-12.69,-2.05,;-13.46,-.72,;-7.3,-.72,;-5.76,-.72,;-5.2,.72,;-3.73,1.17,;2.88,.3,;4.22,1.07,;9.55,1.07,;11.01,.6,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0290	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50110523 (1-{1-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-eth...) Show SMILES C[C@@H](N1CCN(C[C@H]1C)C1CCCCC1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C26H34N2O4S/c1-19-17-27(22-6-4-3-5-7-22)14-15-28(19)20(2)21-8-10-23(11-9-21)33(29,30)24-12-13-25-26(16-24)32-18-31-25/h8-13,16,19-20,22H,3-7,14-15,17-18H2,1-2H3/t19-,20-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.0300	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity against human cloned Muscarinic acetylcholine receptor M2.				Bioorg Med Chem Lett 12: 791-4 (2002) BindingDB Entry DOI: 10.7270/Q2VH5N5J
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50110539 (1-{1-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-eth...) Show SMILES C[C@H](N1CCN(C[C@H]1C)C1CCCCC1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C26H34N2O4S/c1-19-17-27(22-6-4-3-5-7-22)14-15-28(19)20(2)21-8-10-23(11-9-21)33(29,30)24-12-13-25-26(16-24)32-18-31-25/h8-13,16,19-20,22H,3-7,14-15,17-18H2,1-2H3/t19-,20+/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.0300	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity against human cloned Muscarinic acetylcholine receptor M2.				Bioorg Med Chem Lett 12: 791-4 (2002) BindingDB Entry DOI: 10.7270/Q2VH5N5J
					More data for this Ligand-Target Pair
Calcitonin gene-related peptide type 1 receptor (Homo sapiens (Human))	BDBM50447325 (CHEMBL3114676) Show SMILES CC(C)(C)CCN1[C@H](S[C@@H](CC(=O)N2CCC(CC2)N2CCc3ccccc3NC2=O)C1=O)c1cccc(F)c1N1CCN(CC1)C(C)(C)C |r| Show InChI InChI=1S/C39H55FN6O3S/c1-38(2,3)17-21-46-35(48)32(50-36(46)29-11-9-12-30(40)34(29)43-22-24-44(25-23-43)39(4,5)6)26-33(47)42-18-15-28(16-19-42)45-20-14-27-10-7-8-13-31(27)41-37(45)49/h7-13,28,32,36H,14-26H2,1-6H3,(H,41,49)/t32-,36+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	0.0300	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Vertex Pharmaceuticals Inc. Curated by ChEMBL					Assay Description Displacement of [125I]CGRP from CGRP receptor in human SK-N-MC cell membranes preincubated for 30 mins followed by radioligand addition measured afte...				Bioorg Med Chem Lett 24: 845-9 (2014) Article DOI: 10.1016/j.bmcl.2013.12.089 BindingDB Entry DOI: 10.7270/Q2FJ2J84
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50451113 (CHEMBL2114068) Show SMILES COc1ccc(cc1)[S@+]([O-])c1ccc(cc1)C(=C)C1CCN(CC1)C1CCCCC1 |r| Show InChI InChI=1S/C26H33NO2S/c1-20(22-16-18-27(19-17-22)23-6-4-3-5-7-23)21-8-12-25(13-9-21)30(28)26-14-10-24(29-2)11-15-26/h8-15,22-23H,1,3-7,16-19H2,2H3/t30-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.0300	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity against Muscarinic acetylcholine receptor M2				Bioorg Med Chem Lett 10: 2209-12 (2001) BindingDB Entry DOI: 10.7270/Q24T6HMP
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50095111 (4-{(4R,5R)-2-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phe...) Show SMILES CCOC(=O)N1CCC(CC1)N1CCC(CC1)C1(O[C@H](C)[C@@H](C)O1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C31H40N2O8S/c1-4-37-30(34)33-17-13-25(14-18-33)32-15-11-24(12-16-32)31(40-21(2)22(3)41-31)23-5-7-26(8-6-23)42(35,36)27-9-10-28-29(19-27)39-20-38-28/h5-10,19,21-22,24-25H,4,11-18,20H2,1-3H3/t21-,22-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	0.0300	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity at human cloned acetylcholine receptor M2 in CHO cells.				Bioorg Med Chem Lett 10: 2727-30 (2000) BindingDB Entry DOI: 10.7270/Q2V40TGZ
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50095097 (4-{2-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-[1,...) Show SMILES CCCS(=O)(=O)N1CCC(CC1)N1CCC(CC1)C1(SCCS1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C29H38N2O6S4/c1-2-19-40(32,33)31-15-11-24(12-16-31)30-13-9-23(10-14-30)29(38-17-18-39-29)22-3-5-25(6-4-22)41(34,35)26-7-8-27-28(20-26)37-21-36-27/h3-8,20,23-24H,2,9-19,21H2,1H3	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.0310	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity at human cloned acetylcholine receptor M2 in CHO cells.				Bioorg Med Chem Lett 10: 2727-30 (2000) BindingDB Entry DOI: 10.7270/Q2V40TGZ
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593840 (US11578084, Compound I-123 | US11578084, Compound ...) Show SMILES CC(Oc1ccc2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)c3cccc4nn(C)cc34)CCc2n1)C(F)F |r,wU:12.11,wD:15.18,(-7.95,5.11,;-9.28,4.34,;-9.28,2.8,;-7.95,2.03,;-7.95,.49,;-6.62,-.28,;-5.28,.49,;-4.08,-.47,;-2.58,-.13,;-1.91,1.26,;-.37,1.26,;.4,-.07,;1.94,-.07,;2.71,1.26,;4.25,1.26,;5.02,-.07,;4.25,-1.41,;2.71,-1.41,;6.56,-.07,;7.33,-1.41,;6.56,-2.74,;8.87,-1.41,;9.64,-.07,;11.18,-.07,;11.95,-1.41,;11.18,-2.74,;11.66,-4.21,;10.41,-5.11,;10.41,-6.65,;9.17,-4.21,;9.64,-2.74,;-2.58,2.65,;-4.08,2.99,;-5.28,2.03,;-6.62,2.8,;-10.62,5.11,;-11.95,4.34,;-10.62,6.65,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0340	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593735 (US11578084, Compound I-018) Show SMILES Cc1nnc(CC(=O)N[C@H]2CC[C@](F)(CCN3CCc4ccc(OCC(C)(F)F)nc4CC3)CC2)s1 |r,wU:12.13,wD:9.8,12.12,(13.36,1.84,;11.82,1.84,;10.91,.6,;9.45,1.07,;9.45,2.61,;8.11,3.38,;6.78,2.61,;6.78,1.07,;5.45,3.38,;4.11,2.61,;2.78,3.38,;1.44,2.61,;1.44,1.07,;1.44,-.47,;.11,.3,;-1.22,1.07,;-2.56,.3,;-2.44,-1.23,;-3.57,-2.28,;-5.09,-2.05,;-5.86,-3.38,;-7.4,-3.38,;-8.17,-2.05,;-9.71,-2.05,;-10.48,-.72,;-12.02,-.72,;-12.79,.62,;-12.02,-2.26,;-13.36,-1.49,;-7.4,-.72,;-5.86,-.72,;-5.3,.72,;-3.83,1.17,;2.78,.3,;4.11,1.07,;10.91,3.09,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0350	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476836 (US10870660, Compound III-581 | US11345716, Compoun...) Show SMILES Cc1cc(OCC(=O)N[C@H]2CC[C@H](CCN3CCc4sc(nc4C3)N3CC(F)(F)C3)CC2)no1 |r,wU:12.12,wD:9.8,(13.67,2.46,;12.13,2.46,;11.22,1.21,;9.76,1.69,;8.42,.92,;7.09,1.69,;5.76,.92,;5.76,-.62,;4.42,1.69,;3.09,.92,;1.76,1.69,;.42,.92,;.42,-.62,;-.91,-1.39,;-2.25,-.62,;-3.58,-1.39,;-3.58,-2.93,;-4.91,-3.7,;-6.25,-2.93,;-7.71,-3.41,;-8.62,-2.16,;-7.71,-.92,;-6.25,-1.39,;-4.91,-.62,;-10.16,-2.16,;-11.24,-1.07,;-12.33,-2.16,;-13.67,-1.39,;-13.67,-2.93,;-11.24,-3.25,;1.76,-1.39,;3.09,-.62,;9.76,3.23,;11.22,3.7,)| Show InChI InChI=1S/C23H31F2N5O3S/c1-15-10-21(28-33-15)32-12-20(31)26-17-4-2-16(3-5-17)6-8-29-9-7-19-18(11-29)27-22(34-19)30-13-23(24,25)14-30/h10,16-17H,2-9,11-14H2,1H3,(H,26,31)/t16-,17-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0350	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593733 (US11578084, Compound I-016) Show SMILES Cn1cc2c(cccc2n1)C(=O)NN1CCC(CCN2CCc3ccc(OCC(F)(F)F)nc3CC2)CC1 Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0390	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50110534 (1-Cyclohexyl-4-{1-[4-(4-methoxy-benzenesulfonyl)-p...) Show SMILES COc1ccc(cc1)S(=O)(=O)c1ccc(cc1)[C@@H](C)N1CCN([C@@H](C)C1)C1CCCCC1 Show InChI InChI=1S/C26H36N2O3S/c1-20-19-27(17-18-28(20)23-7-5-4-6-8-23)21(2)22-9-13-25(14-10-22)32(29,30)26-15-11-24(31-3)12-16-26/h9-16,20-21,23H,4-8,17-19H2,1-3H3/t20-,21+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.0400	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity against human cloned Muscarinic acetylcholine receptor M2.				Bioorg Med Chem Lett 12: 791-4 (2002) BindingDB Entry DOI: 10.7270/Q2VH5N5J
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593890 (US11578084, Compound I'-38) Show SMILES Cn1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(C)(F)F)sc4CC3)CC2)n1 |r,wU:12.12,wD:9.8,(13.14,2.67,;11.6,2.67,;10.79,1.36,;9.29,1.72,;9.18,3.26,;7.84,4.03,;6.51,3.26,;6.51,1.72,;5.17,4.03,;3.84,3.26,;2.51,4.03,;1.17,3.26,;1.17,1.72,;-.16,.95,;-1.49,1.72,;-2.83,.95,;-4.1,1.82,;-5.57,1.36,;-6.13,-.07,;-7.64,-.39,;-7.8,-1.92,;-9.14,-2.69,;-10.47,-1.92,;-11.8,-2.69,;-13.14,-1.92,;-12.57,-4.03,;-11.03,-4.03,;-6.4,-2.55,;-5.36,-1.41,;-3.84,-1.64,;-2.71,-.59,;2.51,.95,;3.84,1.72,;10.6,3.84,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0430	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593802 (US11578084, Compound I-085) Show SMILES COc1cc(CC(=O)N[C@H]2CC[C@](F)(CCN3CCc4ccc(OCC(F)F)nc4CC3)CC2)on1 |r,wU:12.13,wD:9.8,12.12,(13.46,.51,;12.69,1.84,;11.15,1.84,;10.24,3.09,;8.78,2.61,;7.45,3.38,;6.11,2.61,;6.11,1.07,;4.78,3.38,;3.45,2.61,;2.11,3.38,;.78,2.61,;.78,1.07,;.78,-.47,;-.56,.3,;-1.89,1.07,;-3.22,.3,;-3.11,-1.23,;-4.24,-2.28,;-5.76,-2.05,;-6.53,-3.38,;-8.07,-3.38,;-8.84,-2.05,;-10.38,-2.05,;-11.15,-.72,;-12.69,-.72,;-13.46,.62,;-13.46,-2.05,;-8.07,-.72,;-6.53,-.72,;-5.97,.72,;-4.5,1.17,;2.11,.3,;3.45,1.07,;8.78,1.07,;10.24,.6,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0440	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593765 (US11578084, Compound I-048) Show SMILES FC(F)c1ncccc1C(=O)N[C@H]1CC[C@H](CCN2CCc3nc(OCC(F)(F)F)sc3CC2)CC1 |r,wU:15.16,wD:12.12,(10.19,-4.77,;9.42,-3.44,;7.88,-3.44,;10.19,-2.1,;11.73,-2.1,;12.5,-.77,;11.73,.56,;10.19,.56,;9.42,-.77,;7.88,-.77,;7.11,-2.1,;7.11,.56,;5.57,.56,;4.8,1.9,;3.26,1.9,;2.49,.56,;.95,.56,;.18,1.9,;-1.36,1.9,;-2.03,.51,;-3.53,.17,;-4.74,1.13,;-6.2,.65,;-7.11,1.9,;-8.65,1.9,;-9.42,3.23,;-10.96,3.23,;-12.5,3.23,;-10.96,4.77,;-10.96,1.69,;-6.2,3.14,;-4.74,2.67,;-3.53,3.63,;-2.03,3.28,;3.26,-.77,;4.8,-.77,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0480	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476923 (US10870660, Compound II-081 | US11345716, Compound...) Show SMILES CCn1c(cccc1=O)C(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(OCC(F)(F)F)nc3CC2)CC1 |r,wU:15.16,wD:12.12,(11.5,-.85,;10.17,-.08,;10.17,1.46,;8.84,2.23,;8.84,3.77,;10.17,4.54,;11.5,3.77,;11.5,2.23,;12.84,1.46,;7.5,1.46,;7.5,-.08,;6.17,2.23,;4.84,1.46,;3.5,2.23,;2.17,1.46,;2.17,-.08,;.84,-.85,;-.5,-.08,;-1.83,-.85,;-1.72,-2.39,;-2.85,-3.43,;-4.37,-3.21,;-5.14,-4.54,;-6.68,-4.54,;-7.45,-3.21,;-8.99,-3.21,;-9.76,-1.87,;-11.3,-1.87,;-12.07,-.54,;-12.07,-3.21,;-12.84,-1.87,;-6.68,-1.87,;-5.14,-1.87,;-4.58,-.44,;-3.1,.02,;3.5,-.85,;4.84,-.08,)| Show InChI InChI=1S/C27H35F3N4O3/c1-2-34-23(4-3-5-25(34)35)26(36)31-21-9-6-19(7-10-21)12-15-33-16-13-20-8-11-24(32-22(20)14-17-33)37-18-27(28,29)30/h3-5,8,11,19,21H,2,6-7,9-10,12-18H2,1H3,(H,31,36)/t19-,21-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0480	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476834 (US10870660, Compound III-578 | US11345716, Compoun...) Show SMILES COc1cc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4sc(nc4C3)N3CC(F)(F)C3)CC2)on1 |r,wU:12.12,wD:9.8,(13.39,2.49,;12.62,1.15,;11.08,1.15,;10.17,2.4,;8.71,1.93,;7.37,2.69,;6.04,1.93,;6.04,.38,;4.7,2.69,;3.37,1.93,;2.04,2.69,;.7,1.93,;.7,.38,;-.63,-.38,;-1.96,.38,;-3.3,-.38,;-3.3,-1.93,;-4.63,-2.69,;-5.96,-1.93,;-7.43,-2.4,;-8.33,-1.15,;-7.43,.09,;-5.96,-.38,;-4.63,.38,;-9.87,-1.15,;-10.96,-.07,;-12.05,-1.15,;-13.39,-.38,;-13.39,-1.93,;-10.96,-2.24,;2.04,-.38,;3.37,.38,;8.71,.38,;10.17,-.09,)| Show InChI InChI=1S/C23H31F2N5O3S/c1-32-21-11-17(33-28-21)10-20(31)26-16-4-2-15(3-5-16)6-8-29-9-7-19-18(12-29)27-22(34-19)30-13-23(24,25)14-30/h11,15-16H,2-10,12-14H2,1H3,(H,26,31)/t15-,16-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0500	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476858 (US10870660, Compound III-706 | US11345716, Compoun...) Show SMILES Cc1nc(\C=C\C(=O)N[C@H]2CC[C@H](CCN3CCc4sc(nc4C3)N3CC(F)(F)C3)CC2)cs1 |r,wU:12.12,wD:9.8,(12.75,4.37,;11.98,3.04,;10.51,2.56,;10.51,1.02,;9.18,.25,;7.84,1.02,;6.51,.25,;6.51,-1.29,;5.18,1.02,;3.84,.25,;2.53,1.02,;1.19,.25,;1.19,-1.29,;-.14,-2.06,;-1.48,-1.29,;-2.81,-2.06,;-2.79,-3.6,;-4.13,-4.37,;-5.46,-3.6,;-6.92,-4.08,;-7.83,-2.83,;-6.92,-1.58,;-5.46,-2.06,;-4.13,-1.29,;-9.37,-2.83,;-10.46,-1.74,;-11.55,-2.83,;-12.88,-2.06,;-12.88,-3.6,;-10.46,-3.92,;2.53,-2.06,;3.86,-1.29,;11.98,.54,;12.88,1.79,)| Show InChI InChI=1S/C24H31F2N5OS2/c1-16-27-19(13-33-16)6-7-22(32)28-18-4-2-17(3-5-18)8-10-30-11-9-21-20(12-30)29-23(34-21)31-14-24(25,26)15-31/h6-7,13,17-18H,2-5,8-12,14-15H2,1H3,(H,28,32)/b7-6+/t17-,18-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0510	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476924 (US10870660, Compound II-084 | US11345716, Compound...) Show SMILES CN(CC(F)(F)F)c1nc2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Cc3cnc(C)s3)CCc2s1 |r,wU:15.14,wD:18.21,(-9.24,-3.94,;-9.24,-2.4,;-10.58,-1.63,;-11.91,-2.4,;-13.24,-3.17,;-12.68,-1.07,;-11.14,-3.73,;-7.91,-1.63,;-7.64,-.12,;-6.11,.09,;-5.44,1.48,;-3.94,1.82,;-2.74,.86,;-1.4,1.63,;-.07,.86,;1.27,1.63,;1.27,3.17,;2.6,3.94,;3.93,3.17,;3.93,1.63,;2.6,.86,;5.27,3.94,;6.6,3.17,;6.6,1.63,;7.93,3.94,;9.27,3.17,;9.43,1.64,;10.93,1.32,;11.7,2.65,;13.24,2.65,;10.67,3.8,;-2.74,-.68,;-3.94,-1.64,;-5.44,-1.3,;-6.55,-2.36,)| Show InChI InChI=1S/C24H34F3N5OS2/c1-16-28-14-19(34-16)13-22(33)29-18-5-3-17(4-6-18)7-10-32-11-8-20-21(9-12-32)35-23(30-20)31(2)15-24(25,26)27/h14,17-18H,3-13,15H2,1-2H3,(H,29,33)/t17-,18-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0520	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476773 (US10870660, Compound III-138 | US11345716, Compoun...) Show SMILES Cn1cc(\C=C\C(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)cn1 |r,wU:12.12,wD:9.8,(12.71,6.09,;11.94,4.76,;10.47,4.28,;10.47,2.74,;9.14,1.97,;7.81,2.74,;6.47,1.97,;6.47,.43,;5.14,2.74,;3.81,1.97,;2.47,2.74,;1.14,1.97,;1.14,.43,;-.2,-.34,;-1.53,.43,;-2.86,-.34,;-4.22,.39,;-5.63,-.21,;-6.04,-1.77,;-7.51,-2.24,;-7.51,-3.78,;-8.84,-4.55,;-10.18,-3.78,;-11.51,-4.55,;-12.84,-3.78,;-11.51,-6.09,;-12.84,-5.32,;-6.04,-4.26,;-5.14,-3.01,;-3.6,-3.01,;-2.59,-1.85,;2.47,-.34,;3.81,.43,;11.94,2.27,;12.84,3.51,)| Show InChI InChI=1S/C24H32F3N5O2S/c1-31-15-18(14-28-31)4-7-22(33)29-19-5-2-17(3-6-19)8-11-32-12-9-20-21(10-13-32)35-23(30-20)34-16-24(25,26)27/h4,7,14-15,17,19H,2-3,5-6,8-13,16H2,1H3,(H,29,33)/b7-4+/t17-,19-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0570	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50451114 (CHEMBL2115128) Show SMILES COc1ccc(cc1)[S@@+]([O-])c1ccc(cc1)C(=C)C1CCN(CC1)C1CCCCC1 |r| Show InChI InChI=1S/C26H33NO2S/c1-20(22-16-18-27(19-17-22)23-6-4-3-5-7-23)21-8-12-25(13-9-21)30(28)26-14-10-24(29-2)11-15-26/h8-15,22-23H,1,3-7,16-19H2,2H3/t30-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.0570	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity against Muscarinic acetylcholine receptor M2				Bioorg Med Chem Lett 10: 2209-12 (2001) BindingDB Entry DOI: 10.7270/Q24T6HMP
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593764 (US11578084, Compound I-047) Show SMILES COC(CN1CCc2sc(OCC(C)(F)F)nc2C1)C1CC2(CC(C2)NC(=O)c2cccc3nn(C)cc23)C1 |(1.42,-3.91,;-.07,-3.51,;-.47,-2.03,;-1.96,-1.63,;-3.05,-2.72,;-2.57,-4.18,;-3.6,-5.33,;-5.11,-5.01,;-6.35,-5.91,;-7.6,-5.01,;-8.93,-5.78,;-10.02,-4.69,;-11.51,-5.09,;-12.6,-4,;-11.11,-6.57,;-12.6,-6.18,;-7.12,-3.54,;-5.58,-3.54,;-4.55,-2.4,;.62,-.94,;.62,.6,;2.16,.6,;3.7,.6,;3.7,2.14,;2.16,2.14,;4.79,3.23,;6.27,2.83,;6.67,1.34,;7.36,3.92,;6.74,5.33,;7.64,6.57,;9.17,6.41,;9.8,5.01,;11.27,4.53,;11.27,2.99,;12.6,2.22,;9.8,2.51,;8.9,3.76,;2.16,-.94,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0580	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476914 (US10870660, Compound II-041) Show SMILES COc1cc(\C=C\C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(OCC(F)F)nc4CC3)CC2)on1 |r,wU:13.13,wD:10.9,(14.13,4.44,;13.36,3.1,;11.82,3.1,;10.91,1.86,;9.45,2.33,;8.11,1.56,;6.78,2.33,;5.45,1.56,;5.45,.02,;4.11,2.33,;2.78,1.56,;1.44,2.33,;.11,1.56,;.11,.02,;-1.22,-.75,;-2.56,.02,;-3.89,-.75,;-3.77,-2.28,;-4.9,-3.33,;-6.43,-3.1,;-7.2,-4.44,;-8.74,-4.44,;-9.51,-3.1,;-11.05,-3.1,;-11.82,-1.77,;-13.36,-1.77,;-14.13,-.43,;-14.13,-3.1,;-8.74,-1.77,;-7.2,-1.77,;-6.63,-.33,;-5.16,.12,;1.44,-.75,;2.78,.02,;9.45,3.87,;10.91,4.35,)| Show InChI InChI=1S/C26H34F2N4O4/c1-34-26-16-21(36-31-26)7-8-24(33)29-20-5-2-18(3-6-20)10-13-32-14-11-19-4-9-25(35-17-23(27)28)30-22(19)12-15-32/h4,7-9,16,18,20,23H,2-3,5-6,10-15,17H2,1H3,(H,29,33)/b8-7+/t18-,20-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0580	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476925 (US10870660, Compound II-087) Show SMILES Cn1cc2c(cccc2n1)C(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(OCC(F)(F)F)nc3CC2)OC1 |r| Show InChI InChI=1S/C27H32F3N5O3/c1-34-15-22-21(3-2-4-24(22)33-34)26(36)31-19-6-7-20(37-16-19)10-13-35-12-9-18-5-8-25(32-23(18)11-14-35)38-17-27(28,29)30/h2-5,8,15,19-20H,6-7,9-14,16-17H2,1H3,(H,31,36)/t19-,20+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0590	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593734 (US11578084, Compound I-017) Show SMILES Cn1cc(CC(=O)N[C@H]2CC[C@](F)(CCN3CCc4ccc(OCC(C)(F)F)nc4CC3)CC2)cn1 |r,wU:11.12,wD:8.7,11.11,(13.36,1.84,;11.82,1.84,;10.91,3.09,;9.45,2.61,;8.11,3.38,;6.78,2.61,;6.78,1.07,;5.45,3.38,;4.11,2.61,;2.78,3.38,;1.44,2.61,;1.44,1.07,;1.44,-.47,;.11,.3,;-1.22,1.07,;-2.56,.3,;-2.44,-1.23,;-3.57,-2.28,;-5.09,-2.05,;-5.86,-3.38,;-7.4,-3.38,;-8.17,-2.05,;-9.71,-2.05,;-10.48,-.72,;-12.02,-.72,;-12.79,.62,;-12.02,-2.26,;-13.36,-1.49,;-7.4,-.72,;-5.86,-.72,;-5.3,.72,;-3.83,1.17,;2.78,.3,;4.11,1.07,;9.45,1.07,;10.91,.6,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0630	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476759 (US10870660, Compound III-027 | US11345716, Compoun...) Show SMILES Cn1cc2c(cccc2n1)C(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(OCC(C)(F)F)nc3CC2)CC1 |r,wU:16.18,wD:13.14,(12.71,-1.54,;11.94,-.21,;10.41,-.05,;10.09,1.46,;8.76,2.23,;8.76,3.77,;10.09,4.54,;11.42,3.77,;11.42,2.23,;12.57,1.2,;7.42,1.46,;7.42,-.08,;6.09,2.23,;4.76,1.46,;3.42,2.23,;2.09,1.46,;2.09,-.08,;.76,-.85,;-.58,-.08,;-1.91,-.85,;-1.8,-2.39,;-2.93,-3.43,;-4.45,-3.21,;-5.22,-4.54,;-6.76,-4.54,;-7.53,-3.21,;-9.07,-3.21,;-9.84,-1.87,;-11.38,-1.87,;-12.15,-.54,;-11.38,-3.41,;-12.71,-2.64,;-6.76,-1.87,;-5.22,-1.87,;-4.66,-.44,;-3.18,.02,;3.42,-.85,;4.76,-.08,)| Show InChI InChI=1S/C29H37F2N5O2/c1-29(30,31)19-38-27-11-8-21-13-16-36(17-14-25(21)33-27)15-12-20-6-9-22(10-7-20)32-28(37)23-4-3-5-26-24(23)18-35(2)34-26/h3-5,8,11,18,20,22H,6-7,9-10,12-17,19H2,1-2H3,(H,32,37)/t20-,22-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0640	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (RAT)	BDBM50121132 ((4-{2-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-[1...) Show SMILES Cc1ccccc1C(=O)N1CCC(CC1)N1CCC(CC1)C1(OCCO1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C34H38N2O7S/c1-24-4-2-3-5-30(24)33(37)36-18-14-27(15-19-36)35-16-12-26(13-17-35)34(42-20-21-43-34)25-6-8-28(9-7-25)44(38,39)29-10-11-31-32(22-29)41-23-40-31/h2-11,22,26-27H,12-21,23H2,1H3	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	0.0650	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity towards Muscarinic acetylcholine receptor M2				Bioorg Med Chem Lett 12: 3479-82 (2002) BindingDB Entry DOI: 10.7270/Q2VT1RGD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476866 (US10870660, Compound II-053 | US11345716, Compound...) Show SMILES Cc1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)s1 |r,wU:12.12,wD:9.8,(13.21,2.4,;11.67,2.4,;10.77,1.16,;9.3,1.63,;9.3,3.17,;7.97,3.94,;6.63,3.17,;6.63,1.63,;5.3,3.94,;3.97,3.17,;2.63,3.94,;1.3,3.17,;1.3,1.63,;-.03,.86,;-1.37,1.63,;-2.7,.86,;-3.91,1.82,;-5.41,1.48,;-6.08,.09,;-7.6,-.12,;-7.88,-1.63,;-9.21,-2.4,;-10.54,-1.63,;-11.88,-2.4,;-11.88,-3.94,;-13.21,-1.63,;-13.21,-3.17,;-6.52,-2.36,;-5.41,-1.3,;-3.91,-1.64,;-2.7,-.68,;2.63,.86,;3.97,1.63,;10.77,3.65,)| Show InChI InChI=1S/C23H31F3N4O2S2/c1-15-27-13-18(33-15)12-21(31)28-17-4-2-16(3-5-17)6-9-30-10-7-19-20(8-11-30)34-22(29-19)32-14-23(24,25)26/h13,16-17H,2-12,14H2,1H3,(H,28,31)/t16-,17-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0670	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M4 (Homo sapiens (Human))	BDBM50092313 (1-Cyclohexyl-4-{1-[4-(4-methoxy-benzenesulfinyl)-p...) Show SMILES COc1ccc(cc1)S(=O)c1ccc(cc1)C(C)C1CCN(CC1)C1CCCCC1 Show InChI InChI=1S/C26H35NO2S/c1-20(22-16-18-27(19-17-22)23-6-4-3-5-7-23)21-8-12-25(13-9-21)30(28)26-14-10-24(29-2)11-15-26/h8-15,20,22-23H,3-7,16-19H2,1-2H3	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	0.0700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity against Muscarinic acetylcholine receptor M4				Bioorg Med Chem Lett 10: 2209-12 (2001) BindingDB Entry DOI: 10.7270/Q24T6HMP
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50092959 (4-{1-[4-(4-Methoxy-benzenesulfonyl)-phenyl]-vinyl}...) Show SMILES CCOC(=O)N1CCC(CC1)N1CCC(CC1)C(=C)c1ccc(cc1)S(=O)(=O)c1ccc(OC)cc1 Show InChI InChI=1S/C28H36N2O5S/c1-4-35-28(31)30-19-15-24(16-20-30)29-17-13-23(14-18-29)21(2)22-5-9-26(10-6-22)36(32,33)27-11-7-25(34-3)8-12-27/h5-12,23-24H,2,4,13-20H2,1,3H3	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	0.0700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity at human cloned acetylcholine receptor M2 in CHO cells.				Bioorg Med Chem Lett 10: 2727-30 (2000) BindingDB Entry DOI: 10.7270/Q2V40TGZ
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593796 (US11578084, Compound I-079) Show SMILES Cc1cc(OCC(=O)N[C@H]2CC[C@](F)(CCN3CCc4ccc(OCC(C)(F)F)nc4CC3)CC2)no1 |r,wU:12.13,wD:9.8,12.12,(14.02,3.15,;12.48,3.15,;11.58,1.9,;10.11,2.38,;8.78,1.61,;7.45,2.38,;6.11,1.61,;6.11,.07,;4.78,2.38,;3.45,1.61,;2.11,2.38,;.78,1.61,;.78,.07,;.78,-1.47,;-.56,-.7,;-1.89,.07,;-3.22,-.7,;-3.11,-2.24,;-4.24,-3.29,;-5.76,-3.06,;-6.53,-4.39,;-8.07,-4.39,;-8.84,-3.06,;-10.38,-3.06,;-11.15,-1.72,;-12.69,-1.72,;-13.46,-.39,;-12.69,-3.26,;-14.02,-2.49,;-8.07,-1.72,;-6.53,-1.72,;-5.97,-.29,;-4.5,.16,;2.11,-.7,;3.45,.07,;10.11,3.92,;11.58,4.39,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
Calcitonin gene-related peptide type 1 receptor (Homo sapiens (Human))	BDBM50447328 (CHEMBL3114494) Show SMILES CCN1CCN(CC1)c1c(F)cccc1C1SC(CC(=O)N2CCC(CC2)N2CCc3ccccc3NC2=O)C(=O)N1CCC(C)(C)C Show InChI InChI=1S/C37H51FN6O3S/c1-5-40-21-23-42(24-22-40)33-28(10-8-11-29(33)38)35-44(20-16-37(2,3)4)34(46)31(48-35)25-32(45)41-17-14-27(15-18-41)43-19-13-26-9-6-7-12-30(26)39-36(43)47/h6-12,27,31,35H,5,13-25H2,1-4H3,(H,39,47)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	0.0700	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Vertex Pharmaceuticals Inc. Curated by ChEMBL					Assay Description Displacement of [125I]CGRP from CGRP receptor in human SK-N-MC cell membranes preincubated for 30 mins followed by radioligand addition measured afte...				Bioorg Med Chem Lett 24: 845-9 (2014) Article DOI: 10.1016/j.bmcl.2013.12.089 BindingDB Entry DOI: 10.7270/Q2FJ2J84
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593888 (US11578084, Compound I'-36) Show SMILES Cn1ncc(CC(=O)N[C@H]2CC[C@H](CCN3CCc4nc(OCC(F)(F)F)sc4CC3)CC2)n1 |r,wU:12.12,wD:9.8,(13.14,2.77,;11.6,2.77,;10.79,1.46,;9.29,1.83,;9.18,3.36,;7.84,4.13,;6.51,3.36,;6.51,1.82,;5.17,4.13,;3.84,3.36,;2.51,4.13,;1.17,3.36,;1.17,1.82,;-.16,1.05,;-1.49,1.82,;-2.83,1.05,;-4.1,1.92,;-5.57,1.46,;-6.13,.03,;-7.64,-.29,;-7.8,-1.82,;-9.14,-2.59,;-10.47,-1.82,;-11.8,-2.59,;-13.14,-3.36,;-11.8,-4.13,;-13.14,-1.82,;-6.4,-2.45,;-5.36,-1.3,;-3.84,-1.53,;-2.71,-.48,;2.51,1.05,;3.84,1.82,;10.6,3.95,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0710	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593860 (US11578084, Compound I'-8) Show SMILES Cc1cc(OCC(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(CCC(F)(F)F)nc4CC3)CC2)no1 |r,wU:12.12,wD:9.8,(14.13,3.15,;12.59,3.15,;11.68,1.9,;10.22,2.38,;8.88,1.61,;7.55,2.38,;6.22,1.61,;6.22,.07,;4.88,2.38,;3.55,1.61,;2.21,2.38,;.88,1.61,;.88,.07,;-.45,-.7,;-1.79,.07,;-3.12,-.7,;-3,-2.24,;-4.13,-3.29,;-5.66,-3.06,;-6.43,-4.39,;-7.97,-4.39,;-8.74,-3.06,;-10.28,-3.06,;-11.05,-1.72,;-12.59,-1.72,;-13.36,-.39,;-13.36,-3.06,;-14.13,-1.72,;-7.97,-1.72,;-6.43,-1.72,;-5.86,-.29,;-4.39,.16,;2.21,-.7,;3.55,.07,;10.22,3.92,;11.68,4.39,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0710	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593840 (US11578084, Compound I-123 | US11578084, Compound ...) Show SMILES CC(Oc1ccc2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)c3cccc4nn(C)cc34)CCc2n1)C(F)F |r,wU:12.11,wD:15.18,(-7.95,5.11,;-9.28,4.34,;-9.28,2.8,;-7.95,2.03,;-7.95,.49,;-6.62,-.28,;-5.28,.49,;-4.08,-.47,;-2.58,-.13,;-1.91,1.26,;-.37,1.26,;.4,-.07,;1.94,-.07,;2.71,1.26,;4.25,1.26,;5.02,-.07,;4.25,-1.41,;2.71,-1.41,;6.56,-.07,;7.33,-1.41,;6.56,-2.74,;8.87,-1.41,;9.64,-.07,;11.18,-.07,;11.95,-1.41,;11.18,-2.74,;11.66,-4.21,;10.41,-5.11,;10.41,-6.65,;9.17,-4.21,;9.64,-2.74,;-2.58,2.65,;-4.08,2.99,;-5.28,2.03,;-6.62,2.8,;-10.62,5.11,;-11.95,4.34,;-10.62,6.65,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0720	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
Muscarinic acetylcholine receptor M2 (Homo sapiens (Human))	BDBM50095112 (4-{2-[4-(Benzo[1,3]dioxole-5-sulfonyl)-phenyl]-[1,...) Show SMILES CCOC(=O)N1CCC(CC1)N1CCC(CC1)C1(OCCO1)c1ccc(cc1)S(=O)(=O)c1ccc2OCOc2c1 Show InChI InChI=1S/C29H36N2O8S/c1-2-35-28(32)31-15-11-23(12-16-31)30-13-9-22(10-14-30)29(38-17-18-39-29)21-3-5-24(6-4-21)40(33,34)25-7-8-26-27(19-25)37-20-36-26/h3-8,19,22-23H,2,9-18,20H2,1H3	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	0.0730	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Schering-Plough Research Institute Curated by ChEMBL					Assay Description Binding affinity at human cloned acetylcholine receptor M2 in CHO cells.				Bioorg Med Chem Lett 10: 2727-30 (2000) BindingDB Entry DOI: 10.7270/Q2V40TGZ
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens)	BDBM593845 (US11578084, Compound I-128) Show SMILES C[C@@H](Oc1ccc2CCN(CC[C@H]3CC[C@@H](CC3)NC(=O)Cc3cnn(C)n3)CCc2n1)C(F)(F)F |r,wU:1.0,12.11,wD:15.18,(-9.61,.62,;-10.38,-.72,;-9.61,-2.05,;-8.07,-2.05,;-7.3,-3.38,;-5.76,-3.38,;-4.99,-2.05,;-3.47,-2.28,;-2.34,-1.23,;-2.45,.3,;-1.12,1.07,;.21,.3,;1.55,1.07,;1.55,2.61,;2.88,3.38,;4.22,2.61,;4.22,1.07,;2.88,.3,;5.55,3.38,;6.88,2.61,;6.88,1.07,;8.22,3.38,;9.55,2.61,;9.55,1.07,;11.01,.6,;11.92,1.84,;13.46,1.84,;11.01,3.09,;-3.73,1.17,;-5.2,.72,;-5.76,-.72,;-7.3,-.72,;-11.92,-.72,;-12.69,-2.05,;-12.69,.62,;-13.46,-.72,)| Show InChI	PDB KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0730	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Buffer solution: 50 mM Tris-HCl (35409-45, Nacalai Tesque) (pH 7.4) containing 120 mM NaCl (31320-05, Nacalai Tesque), 1 mM MgCl.6HO (20909-55, Nacal...				Citation and Details BindingDB Entry DOI: 10.7270/Q2CF9V1Q
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476922 (US10870660, Compound II-078 | US11345716, Compound...) Show SMILES Cc1cc(OCC(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(OCC(F)(F)F)nc4CC3)CC2)no1 |r,wU:12.12,wD:9.8,(14.16,2.98,;12.62,2.98,;11.59,1.83,;10.18,2.46,;8.85,1.69,;7.52,2.46,;6.18,1.69,;6.18,.15,;4.85,2.46,;3.51,1.69,;2.18,2.46,;.85,1.69,;.85,.15,;-.49,-.62,;-1.82,.15,;-3.15,-.62,;-3.04,-2.16,;-4.17,-3.21,;-5.69,-2.98,;-6.46,-4.31,;-8,-4.31,;-8.77,-2.98,;-10.31,-2.98,;-11.08,-1.64,;-12.62,-1.64,;-13.39,-.31,;-13.39,-2.98,;-14.16,-1.64,;-8,-1.64,;-6.46,-1.64,;-5.9,-.21,;-4.43,.25,;2.18,-.62,;3.51,.15,;10.34,3.99,;11.85,4.31,)| Show InChI InChI=1S/C25H33F3N4O4/c1-17-14-24(31-36-17)34-15-22(33)29-20-5-2-18(3-6-20)8-11-32-12-9-19-4-7-23(30-21(19)10-13-32)35-16-25(26,27)28/h4,7,14,18,20H,2-3,5-6,8-13,15-16H2,1H3,(H,29,33)/t18-,20-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0750	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair
D(3) dopamine receptor (Homo sapiens (Human))	BDBM476838 (US10870660, Compound III-610 | US11345716, Compoun...) Show SMILES CN1Cc2c(cccc2C(=O)N[C@H]2CC[C@H](CCN3CCc4sc(OCC(F)(F)F)nc4C3)CC2)C1=O |r,wU:15.16,wD:12.12,(11.85,-1.67,;11.08,-.33,;9.55,-.17,;9.23,1.33,;10.57,2.1,;10.57,3.64,;9.23,4.41,;7.9,3.64,;7.9,2.1,;6.56,1.33,;6.56,-.21,;5.23,2.1,;3.9,1.33,;2.56,2.1,;1.23,1.33,;1.23,-.21,;-.1,-.98,;-1.44,-.21,;-2.77,-.98,;-2.77,-2.52,;-4.1,-3.29,;-5.44,-2.52,;-6.9,-2.99,;-7.81,-1.75,;-9.35,-1.75,;-10.12,-3.08,;-11.66,-3.08,;-12.43,-4.41,;-13.2,-3.08,;-12.43,-1.75,;-6.9,-.5,;-5.44,-.98,;-4.1,-.21,;2.56,-.98,;3.9,-.21,;11.71,1.07,;13.2,1.47,)| Show InChI InChI=1S/C26H31F3N4O3S/c1-32-13-20-18(3-2-4-19(20)24(32)35)23(34)30-17-7-5-16(6-8-17)9-11-33-12-10-22-21(14-33)31-25(37-22)36-15-26(27,28)29/h2-4,16-17H,5-15H2,1H3,(H,30,34)/t16-,17-	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	0.0770	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SHIONOGI & CO., LTD. US Patent					Assay Description 225 nL of the solutions of the non-specific ligand or the compounds of the present invention at each concentration (in case of vehicle, final concent...				US Patent US10870660 (2020) BindingDB Entry DOI: 10.7270/Q2M61PBD
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 5357 total )  |  Next  |  Last  >>

Jump to: